End of induction positron emission tomography complete response (PET-CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma.
PET-CR
follicular lymphoma
previously untreated
progression-free survival
surrogate end-point
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
07
04
2022
received:
23
02
2022
accepted:
13
04
2022
pubmed:
3
5
2022
medline:
19
7
2022
entrez:
2
5
2022
Statut:
ppublish
Résumé
Progression-free survival (PFS) has been the regulatory primary end-point for recent phase III trials in first-line follicular lymphoma (FL), but requires prolonged follow-up. Complete response (CR) at 30 months after initiation of induction treatment was validated as surrogate end-point for PFS. Our objective was to further evaluate surrogacy of CR measured by [
Substances chimiques
Biomarkers
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-337Informations de copyright
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
Références
Shi Q, Flowers CR, Hiddemann W, Herold M, Hagenbeek A, Kimby E, et al. Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials. J Clin Oncol. 2017 Feb 10;35(5):552-60. https://doi.org/10.1200/JCO.2016.70.8651
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Sep 20;32(27):3059-68. https://doi.org/10.1200/JCO.2013.54.8800
Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014 Oct;1(1):e17-27. https://doi.org/10.1016/S2352-3026(14)70008-0
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. https://doi.org/10.1200/JCO.2006.09.2403
Burzykowski T, Molenberghs G, Buyse M. The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer. J R Stat Soc. 2004;167:103-24. https://doi.org/10.1111/j.1467-985X.2004.00293.x
Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005 Dec 1;23(34):8664-70. https://doi.org/10.1200/JCO.2005.01.6071
Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, et al. Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). J Clin Oncol. 2018 Sep 1;36(25):2593. https://doi.org/10.1200/Jco.2018.77.9124
Yin J, Salem ME, Dixon JG, Jin Z, Cohen R, DeGramont A, et al. Re-evaluating disease-free survival as an endpoint vs overall survival in stage III adjuvant colon cancer trials. J Natl Cancer Inst. 2022;114(1):60-7. https://doi.org/10.1093/jnci/djab187
Burzykowski T, Buyse M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat. 2006 Jul-Sep;5(3):173-86. https://doi.org/10.1002/pst.207
Blum KA, Polley MY, Jung SH, Dockter TJ, Anderson S, Hsi ED, et al. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). Cancer. 2019 Oct 1;125(19):3378-89. https://doi.org/10.1002/cncr.32289
Evens AM, Hong F, Habermann TM, Advani RH, Gascoyne RD, Witzig TE, et al. A three-arm randomized phase II study of bendamustine/rituximab with bortezomib induction or lenalidomide continuation in untreated follicular lymphoma: ECOG-ACRIN E2408. Clin Cancer Res. 2020 Sep 1;26(17):4468-77. https://doi.org/10.1158/1078-0432.CCR-20-1345
Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 Apr 20;31(12):1506-13. https://doi.org/10.1200/JCO.2012.45.0866
Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018 Mar 1;36(7):689-96. https://doi.org/10.1200/JCO.2017.74.1652
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-44. https://doi.org/10.1056/NEJMoa1614598
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018 Sep 6;379(10):934-47. https://doi.org/10.1056/NEJMoa1805104